ArriVent BioPharma shares sink after Phase 3 trial miss
ArriVent BioPharma said its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. The stock fell sharply in premarket trading and touched a 52-week low near $12.09.
ArriVent BioPharma said its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. The stock fell sharply in premarket trading and touched a 52-week low near $12.09.